Viral and cellular cytokines as therapeutic targets in AIDS-related lymphoproliferative disorders

Current Drug Targets - Cardiovascular and Haematological Disorders

Volumn 3, Issue 1, 2003, Pages 81-96

  Aoki, Yoshiyasu ^a   Tosato, Giovanna ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

AIDS; Angiogenesis; Autocrine growth factors; EBV; HAART; HIV; KSHV; MCD; NHL; PEL

Indexed keywords

ANGIOGENIC FACTOR; CELL NUCLEUS ANTIGEN; CYCLIN D; CYTOKINE; FLICE INHIBITORY PROTEIN; G PROTEIN COUPLED RECEPTOR; GLYCOPROTEIN GP 130; GROWTH FACTOR; IM 862; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; JANUS KINASE; MACROPHAGE INFLAMMATORY PROTEIN; MONOCLONAL ANTIBODY; MYC PROTEIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PICEATANNOL; PROTEIN BCL 2; SEMAXANIB; STAT PROTEIN; STAT3 PROTEIN; SYNDECAN 1; TRANSACTIVATOR PROTEIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VIRUS PROTEIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; AUTOCRINE EFFECT; B CELL LYMPHOMA; CANCER GRADING; CANCER INCIDENCE; CARCINOGENESIS; CELL LINEAGE; DEREGULATION; DISEASE ASSOCIATION; DRUG USE; GENETIC CODE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 8; IN VIVO STUDY; LYMPH NODE METASTASIS; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; PHENOTYPE; PRIMARY EFFUSION LYMPHOMA; PROTEIN TARGETING; REVIEW; SURVIVAL TIME; TREATMENT PLANNING; VIROGENESIS; VIRUS GENE;

ANIMALS; CYTOKINES; DRUG DELIVERY SYSTEMS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOPROLIFERATIVE DISORDERS;

EID: 0037369354     PISSN: 15680061     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568006033337294     Document Type: Review

References (178)

1. Ho, D.D., Neumann, A.U., Perelson, A.S., Chen, W., Leonard, J.M., Markowitz, M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 1995, 373, 123-126.
2. Mocroft, A., Katlama, C., Johnson, A.M., Pradier, C., Antunes, F., Mulcahy, F., Chiesi, A., Phillips, A.N., Kirk, O., Lundgren, J.D. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet, 2000, 356, 291-296.
3. Gulick, R.M., Mellors, J.W., Havlir, D., Eron, J.J., Gonzalez, C., McMahon, D., Richman, D.D., Valentine, F.T., Jonas, L., Meibohm, A., Emini, E.A., Chodakewitz, J.A. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med., 1997, 337, 734-739.
4. Staszewski, S., Keiser, P., Montaner, J., Raffi, F., Gathe, J., Brotas, V., Hicks, C., Hammer, S.M., Cooper, D., Johnson, M., Tortell, S., Cutrell, A., Thorborn, D., Isaacs, R., Hetherington, S., Steel, H., Spreen, W. Abacavirlamivudine-zidovudine vs indinavir-lamivudine zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA, 2001, 285, 1155-1163.
5. Palella, F.J., Jr., Delaney, K.M., Moorman, A.C., Loveless, M.O., Fuhrer, J., Satten, G.A., Aschman, D.J., Holmberg, S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med., 1998, 338, 853-860.
6. Petruckevitch, A., Del Amo, J., Phillips, A.N., Johnson, A.M., Stephenson, J., Desmond, N., Hanscheid, T., Low, N., Newell, A., Obasi, A., Paine, K., Pym, A., Theodore, C., De Cock, K.M. Disease progression and survival following specific AIDS-defining conditions: a retrospective cohort study of 2048 HIV-infected persons in London. AIDS, 1998, 12, 1007-1013.
7. Goedert, J.J. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol., 2000, 27, 390-401.
8. Levine, A.M. Lymphoma complicating immunodeficiency disorders. Ann. Oncol., 1994, 5, 29-35.
9. Little, R.F., Gutierrez, M., Jaffe, E.S., Pau, A., Horne, M., Wilson, W. HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis. JAMA, 2001, 285, 1880-1885.
10. Kaplan, L.D., Straus, D.J., Testa, M.A., Von Roenn, J., Dezube, B.J., Cooley, T.P., Herndier, B., Northfelt, D.W., Huang, J., Tulpule, A., Levine, A.M. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N. Engl. J. Med., 1997, 336, 1641-1648.
11. Levine, A.M., Seneviratne, L., Espina, B.M., Wohl, A.R., Tulpule, A., Nathwani, B.N., Gill, P.S. Evolving characteristics of AIDS-related lymphoma. Blood, 2000, 96, 4084-4090.
12. Little, R.F., Yarchoan, R., Wilson, W.H. Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy. Curr. Opin. Oncol., 2000, 12, 438-444.
13. Cesarman, E., Chang, Y., Moore, P.S., Said, J.W., Knowles, D.M. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS- related body-cavity-based lymphomas. N. Engl. J. Med., 1995, 332, 1186-1191.
14. Ansari, M.Q., Dawson, D.B., Nador, R., Rutherford, C., Schneider, N.R., Latimer, M.J., Picker, L., Knowles, D.M., McKenna, R.W. Primary body cavity-based AIDS-related lymphomas. Am. J. Clin. Pathol., 1996, 105, 221-229.
15. Nador, R.G., Cesarman, E., Chadburn, A., Dawson, D.B., Ansari, M.Q., Sald, J., Knowles, D.M. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood, 1996, 88, 645-656.
16. Soulier, J., Grollet, L., Oksenhendler, E., Cacoub, P., Cazals-Hatem, D., Babinet, P., d'Agay, M.F., Clauvel, J.P., Raphael, M., Degos, L., Sigaux, F. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood, 1995, 86, 1276-1280.
17. Parravicini, C., Corbellino, M., Paulli, M., Magrini, U., Lazzarino, M., Moore, P.S., Chang, Y. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am. J. Pathol., 1997, 151, 1517-1522.
18. Oksenhendler, E., Carcelain, G., Aoki, Y., Boulanger, E., Maillard, A., Clauvel, J.P., Agbalika, F. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood, 2000, 96, 2069-2073.
19. Weisenburger, D.D. Multicentric angiofollicular lymph node hyperplasia. Pathology of the spleen. Am. J. Surg. Pathol., 1988, 12, 176-181.
20. Peterson, B.A., Frizzera, G. Multicentric Castleman's disease. Semin Oncol., 1993, 20, 636-647.
21. Soulier, J., Grollet, L., Oksenhendler, E., Miclea, J.M., Cacoub, P., Baruchel, A., Brice, P., Clauvel, J.P., d'Agay, M.F., Raphael, M., Sigaux, F. Molecular analysis of clonality in Castleman's disease. Blood, 1995, 86, 1131-1138.
22. Oksenhendler, E., Duarte, M., Soulier, J., Cacoub, P., Welker, Y., Cadranel, J., Cazals-Hatem, D., Autran, B., Clauvel, J.P., Raphael, M. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS, 1996, 10, 61-67.
23. Zietz, C., Bogner, J.R., Goebel, F.D., Lohrs, U. An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. N. Engl. J. Med., 1999, 340, 1923-1924.
24. Dupin, N., Diss, T.L., Kellam, P., Tulliez, M., Du, M.Q., Sicard, D., Weiss, R.A., Isaacson, P.G., Boshoff, C. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood, 2000, 95, 1406-1412.
25. Frisch, M., Biggar, R.J., Engels, E.A., Goedert, J.J. Association of cancer with AIDS-related immunosuppression in adults. JAMA, 2001, 285, 1736-1745.
26. Carbone, A., Gloghini, A., Larocca, L.M., Capello, D., Pierconti, F., Canzonieri, V., Tirelli, U., Dalla-Favera, R., Gaidano, G. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood, 2001, 97, 744-751.
27. Davi, F., Delecluse, H.J., Guiet, P., Gabarre, J., Fayon, A., Gentilhomme, O., Felman, P., Bayle, C., Berger, F., Audouin, J., Bryon, P.A., Diebold, J., Raphael, M. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group. J. Clin. Oncol., 1998, 16, 3788-3795.
28. Subar, M., Neri, A., Inghirami, G., Knowles, D.M., Dalla-Favera, R. Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma. Blood, 1988, 72, 667-671.
29. Shibata, D., Weiss, L.M., Hernandez, A.M., Nathwani, B.N., Bernstein, L., Levine, A.M. Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Blood, 1993, 81, 2102-2109.
30. Raphael, M.M., Audouin, J., Lamine, M., Delecluse, H.J., Vuillaume, M., Lenoir, G.M., Gisselbrecht, C., Lennert, K., Diebold, J. Immunophenotypic and genotypic analysis of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Correlation with histologic features in 36 cases. French Study Group of Pathology for HIV- Associated Tumors. Am. J. Clin. Pathol., 1994, 101, 773-782.
31. Sparano, J.A. Clinical aspects and management of AIDS-related lymphoma. Eur. J. Cancer, 2001, 37, 1296-1305.
32. Gill, P.S., Levine, A.M., Krailo, M., Rarick, M.U., Loureiro, C., Deyton, L., Meyer, P., Rasheed, S. AIDS-related malignant lymphoma: results of prospective treatment trials. J. Clin. Oncol., 1987, 5, 1322-1328.
33. Knowles, D.M., Inghirami, G., Ubriaco, A., Dalla-Favera, R. Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic role of the Epstein-Barr virus. Blood, 1989, 73, 792-799.
34. Carbone, A., Gaidano, G., Gloghini, A., Larocca, L.M., Capello, D., Canzonieri, V., Antinori, A., Tirelli, U., Falini, B., Dalla-Favera, R. Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood, 1998, 91, 747-755.
35. Said, J.W., Tasaka, T., Takeuchi, S., Asou, H., de Vos, S., Cesarman, E., Knowles, D.M., Koeffler, H.P. Primary effusion lymphoma in women: report of two cases of Kaposi's sarcoma herpes virus-associated effusion-based lymphoma in human immunodeficiency virus-negative women. Blood, 1996, 88, 3124-3128.
36. Boshoff, C., Gao, S.J., Healy, L.E., Matthews, S., Thomas, A.J., Coignet, L., Warnke, R.A., Strauchen, J.A., Matutes, E., Kamel, O.W., Moore, P.S., Weiss, R.A., Chang, Y. Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood, 1998, 91, 1671-1679.
37. Chang, Y., Cesarman, E., Pessin, M.S., Lee, F., Culpepper, J., Knowles, D.M., Moore, P.S. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science, 1994, 266, 1865-1869.
38. Ambroziak, J.A., Blackbourn, D.J., Herndier, B.G., Glogau, R.G., Gullett, J.H., McDonald, A.R., Lennette, E.T., Levy, J.A. Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients [letter; comment]. Science, 1995, 268, 582-583.
39. Castleman, B., Iverson, L., Menendez, V.P. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer, 1956, 9, 822-830.
40. Keller, A.R., Hochholzer, L., Castleman, B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer, 1972, 29, 670-683.
41. Weisenburger, D.D. Multicentric angiofollicular lymph node hyperplasia. Pathology of the spleen. Am. J. Sug. Pathol., 1988, 12, 176-181.
42. Harris, N.L. Hypervascular follicular hyperplasia and Kaposi's sarcoma in patients at risk for AIDS. N. Engl. J. Med., 1984, 310, 462-463.
43. Weisenburger, D.D., Nathwani, B.N., Winberg, C.D., Rappaport, H. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum. Pathol., 1985, 16, 162-172.
44. Du, M.Q., Liu, H., Diss, T.C., Ye, H., Hamoudi, R.A., Dupin, N., Meignin, V., Oksenhendler, E., Boshoff, C., Isaacson, P.G. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood, 2001, 97, 2130-2136.
45. Dupin, N., Fisher, C., Kellam, P., Ariad, S., Tulliez, M., Franck, N., van Marck, E., Salmon, D., Gorin, I., Escande, J.P., Weiss, R.A., Alitalo, K., Boshoff, C. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc. Natl. Acad. Sci. USA, 1999, 96, 4546-4551.
46. Corbellino, M., Bestetti, G., Scalamogna, C., Calattini, S., Galazzi, M., Meroni, L., Manganaro, D., Fasan, M., Moroni, M., Galli, M., Parravicini, C. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood, 2001, 98, 3473-3475.
47. Boshoff, C., Endo, Y., Collins, P.D., Takeuchi, Y., Reeves, J.D., Schweickart, V.L., Siani, M.A., Sasaki, T., Williams, T.J., Gray, P.W., Moore, P.S., Chang, Y., Weiss, R.A. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science, 1997, 278, 290-294.
48. Neipel, F., Albrecht, J.C., Fleckenstein, B. Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity? J. Virol., 1997, 71, 4187-4192.
49. Li, M., Lee, H., Guo, J., Neipel, F., Fleckenstein, B., Ozato, K., Jung, J.U. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor. J. Virol., 1998, 72, 5433-5440.
50. Bais, C., Santomasso, B., Coso, O., Arvanitakis, L., Raaka, E.G., Gutkind, J.S., Asch, A.S., Cesarman, E., Gershengorn, M.C., Mesri, E.A., Gerhengorn, M.C. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature, 1998, 391, 86-89.
51. Cheng, E.H., Nicholas, J., Bellows, D.S., Hayward, G.S., Guo, H.G., Reitz, M.S., Hardwick, J.M. A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc. Natl. Acad. Sci. USA, 1997, 94, 690-694.
52. Djerbi, M., Screpanti, V., Catrina, A.I., Bogen, B., Biberfeld, P., Grandien, A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med., 1999, 190, 1025-1032.
53. Ellis, M., Chew, Y.P., Fallis, L., Freddersdorf, S., Boshoff, C., Weiss, R.A., Lu, X., Mittnacht, S. Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex. EMBO J., 1999, 18, 644-653.
54. Ojala, P.M., Yamamoto, K., Castanos-Velez, E., Biberfeld, P., Korsmeyer, S.J., Makela, T.P. The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates Bcl- 2. Nat. Cell Biol., 2000, 2, 819-825.
55. Sun, R., Lin, S.F., Staskus, K., Gradoville, L., Grogan, E., Haase, A., Miller, G. Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J. Virol., 1999, 73, 2232-2242.
56. Friborg, J., Jr., Kong, W., Hottiger, M.O., Nabel, G.J. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature, 1999, 402, 889-894.
57. Radkov, S.A., Kellam, P., Boshoff, C. The latent nuclear antigen of kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene bras transforms primary rat cells. Nat. Med., 2000, 6, 1121-1127.
58. Aoki, Y., Yarchoan, R., Braun, J., Iwamoto, A., Tosato, G. Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions. Blood, 2000, 96, 1599-1601.
59. Tosato, G., Seamon, K.B., Goldman, N.D., Sehgal, P.B., May, L.T., Washington, G.C., Jones, K.D., Pike, S.E. Monocyte-derived human B-cell growth factor identified as interferon- beta 2 (BSF-2, IL-6). Science, 1988, 239, 502-504.
60. Tosato, G., Gerrard, T.L., Goldman, N.G., Pike, S.E. Stimulation of EBV-activated human B cells by monocytes and monocyte products. Role of IFN-beta 2/B cell stimulatory factor 2/IL-6. J. Immunol., 1988, 140, 4329-4336.
61. Tosato, G., Pike, S.E. Interferon-beta 2/interleukin 6 is a co-stimulant for human T lymphocytes. J. Immunol., 1988, 141, 1556-1562.
62. Tosato, G., Tanner, J., Jones, K.D., Revel, M., Pike, S.E. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J. Virol., 1990, 64, 3033-3041.
63. Birx, D.L., Redfield, R.R., Tencer, K., Fowler, A., Burke, D.S., Tosato, G. Induction of interleukin-6 during human immunodeficiency virus infection. Blood, 1990, 76, 2303-2310.
64. Tosato, G., Miller, J., Marti, G., Pike, S.E. Accessory function of interleukin-1 and interleukin-6: preferential costimulation of T4 positive lymphocytes. Blood, 1990, 75, 922-930.
65. Tosato, G., Tanner, J., Jones, K.D., Revel, M., Pike, S.E. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J. Virol., 1990, 64, 3033-3041.
66. Tosato, G., Jones, K.D. Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. Blood, 1990, 75, 1305-1310.
67. Tanner, J., Tosato, G. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J. Clin. Invest., 1991, 88, 239-247.
68. Tanner, J.E., Tosato, G. Regulation of B-cell growth and immunoglobulin gene transcription by interleukin-6. Blood, 1992, 79, 452-459.
69. Tosato, G., Jones, K., Breinig, M.K., McWilliams, H.P., McKnight, J.L. Interleukin-6 production in posttransplant lymphoproliferative disease. J. Clin. Invest., 1993, 91, 2806-2814.
70. Birx, D.L., Lewis, M.G., Vahey, M., Tencer, K., Zack, P.M., Brown, C.R., Jahrling, P.B., Tosato, G., Burke, D., Redfield, R. Association of interleukin-6 in the pathogenesis of acutely fatal SIVsmm/PBj-14 in pigtailed macaques. AIDS Res. Hum. Retroviruses, 1993, 9, 1123-1129.
71. Pluda, J.M., Venzon, D.J., Tosato, G., Lietzau, J., Wyvill, K., Nelson, D.L., Jaffe, E.S., Karp, J.E., Broder, S., Yarchoan, R. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J. Clin. Oncol., 1993, 11, 1099-1107.
72. Jones, K., Rivera, C., Sgadari, C., Franklin, J., Max, E.E., Bhatia, K., Tosato, G. Infection of human endothelial cells with Epstein-Barr virus. J. Exp. Med., 1995, 182, 1213-1221.
73. Aoki, Y., Narazaki, M., Kishimoto, T., Tosato, G. Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus. Blood, 2001, 98, 3042-3049.
74. Aoki, Y., Jaffe, E.S., Chang, Y., Jones, K., Teruya-Feldstein, J., Moore, P.S., Tosato, G. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood, 1999, 93, 4034-4043.
75. Aoki, Y., Jones, K.D., Tosato, G. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. J. Hematother Stem. Cell Res., 2000, 9, 137-145.
76. Chow, D., He, X., Snow, A.L., Rose-John, S., Garcia, K.C. Structure of an extracellular gp130 cytokine receptor signaling complex. Science, 2001, 291, 2150-2155.
77. Peters, M., Muller, A.M., Rose-John, S. Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood, 1998, 92, 3495-3504.
78. Laurence, J., Astrin, S.M. Human immunodeficiency virus induction of malignant transformation in human B lymphocytes. Proc. Natl. Acad. Sci. USA, 1991, 88, 7635-7639.
79. Ballerini, P., Gaidano, G., Gong, J.Z., Tassi, V., Saglio, G., Knowles, D.M., Dalla-Favera, R. Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood, 1993, 81, 166-176.
80. Birx, D.L., Redfield, R.R., Tosato, G. Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N. Engl. J. Med., 1986, 314, 874-879.
81. O'Reilly, R.J., Small, T.N., Papadopoulos, E., Lucas, K., Lacerda, J., Koulova, L. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol. Rev., 1997, 157, 195-216.
82. Lieberman, J., Shankar, P., Manjunath, N., Andersson, J. Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood, 2001, 98, 1667-1677.
83. Feichtinger, H., Putkonen, P., Parravicini, C., Li, S.L., Kaaya, E.E., Bottiger, D., Biberfeld, G., Biberfeld, P. Malignant lymphomas in cynomolgus monkeys infected with simian immunodeficiency virus. Am. J. Pathol., 1990, 137, 1311-1315.
84. Maggiorella, M.T., Monardo, F., Koanga-Mogtomo, M.L., Cioe, L., Sernicola, L., Corrias, F., Baroni, C.D., Verani, P., Titti, F. Detection of infectious simian immunodeficiency virus in B- and T-cell lymphomas of experimentally infected macaques. Blood, 1998, 91, 3103-3111.
85. Castanos-Velez, E., Heiden, T., Ekman, M., Lawrence, J., Biberfeld, G., Biberfeld, P. Proliferation and apoptosis-related gene expression in experimental acquired immunodeficiency syndrome-related simian lymphoma. Blood, 1999, 93, 1364-1371.
86. Klinken, S.P., Fredrickson, T.N., Hartley, J.W., Yetter, R.A., Morse, H.C. 3rd Evolution of B cell lineage lymphomas in mice with a retrovirus-induced immunodeficiency syndrome, MAIDS. J. Immunol., 1988, 140, 1123-1131.
87. Morse, H.C., 3rd, Chattopadhyay, S.K., Makino, M., Fredrickson, T.N., Hugin, A.W., Hartley, J.W. Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. AIDS, 1992, 6, 607-621.
88. Aoki, Y., Hiromatsu, K., Usami, J., Makino, M., Igarashi, H., Ogasawara, J., Nagata, S., Yoshikai, Y. Clonal expansion but lack of subsequent clonal deletion of bacterial superantigen-reactive T cells in murine retroviral infection. J. Immunol., 1994, 153, 3611-3621.
89. Aoki, Y., Hiromatsu, K., Arai, T., Usami, J., Makino, M., Ishida, H., Yoshikai, Y. Lethal shock is inducible by lipopolysaccharide but not by superantigen in mice with retrovirus-induced immunodeficiency syndrome. J. Immunol., 1995, 155, 3494-3500.
90. Pluda, J.M., Yarchoan, R., Jaffe, E.S., Feuerstein, I.M., Solomon, D., Steinberg, S.M., Wyvill, K.M., Raubitschek, A., Katz, D., Broder, S. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann. Intern. Med., 1990, 113, 276-282.
91. Yarchoan, R., Venzon, D.J., Pluda, J.M., Lietzau, J., Wyvill, K.M., Tsiatis, A.A., Steinberg, S.M., Broder, S. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann. Intern. Med., 1991, 115, 184-189.
92. Kirk, O., Pedersen, C., Cozzi-Lepri, A., Antunes, F., Miller, V., Gatell, J.M., Katlama, C., Lazzarin, A., Skinhoj, P., Barton, S.E. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood, 2001, 98, 3406-3412.
93. van Baarle, D., Hovenkamp, E., Callan, M.F., Wolthers, K.C., Kostense, S., Tan, L.C., Niesters, H.G., Osterhaus, A.D., McMichael, A.J., van Oers, M.H., Miedema, F. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood, 2001, 98, 146-155.
94. Aoki, Y., Yarchoan, R., Wyvill, K., Okamoto, S., Little, R.F., Tosato, G. Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders. Blood, 2001, 97, 2173-2176.
95. Humphrey, R.W., O'Brien, T.R., Newcomb, F.M., Nishihara, H., Wyvill, K.M., Ramos, G.A., Saville, M.W., Goedert, J.J., Straus, S.E., Yarchoan, R. Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells: association with KS and persistence in patients receiving anti-herpesvirus drugs. Blood, 1996, 88, 297-301.
96. Min, J., Katzenstein, D.A. Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels. AIDS Res. Hum. Retroviruses, 1999, 15, 51-55.
97. Grandadam, M., Dupin, N., Calvez, V., Gorin, I., Blum, L., Kernbaum, S., Sicard, D., Buisson, Y., Agut, H., Escande, J.P., Huraux, J.M. Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J. Infect Dis., 1997, 175, 1198-1201.
98. Aoki, Y., Tosato, G., Fonville, T.W., Pittaluga, S. Serum viral interleukin-6 in AIDS-related multicentric Castleman's disease. Blood, 2001, 97, 2526-2527.
99. Whitby, D., Howard, M.R., Tenant-Flowers, M., Brink, N.S., Copas, A., Boshoff, C., Hatzioannou, T., Suggett, F.E., Aldam, D.M., Denton, A.S., Miller, R.F., Weller I.V.D., Weiss, R.A., Tedder, R.S., Schulz, T.F. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet, 1995, 346, 799-802.
100. Campbell, T.B., Borok, M., Gwanzura, L., MaWhinney, S., White, I.E., Ndemera, B., Gudza, I., Fitzpatrick, L., Schooley, R.T. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS, 2000, 14, 2109-2116.
101. Little, R.F., Wyvill, K.M., Pluda, J.M., Wetles, L., Marshall, V., Figg, W.D., Newcomb, F.M., Tosato, G., Feigal, E., Steinberg, S.M., Whitby, D., Goedert, J.J., Yarchoan, R. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J. Clin. Oncol., 2000, 18, 2593-2602.
102. Nunez, M., Saballs, P., Valencia, M.E., Santos, J., Ferrer, E., Santos, I., Berrocal, A., Galindo, M.J., Podzamczer, D., Gonzlez-Lahoz, J. Response to liposomal doxorubicin and clinical outcome of HIV-1- infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy. HIV Clin. Trials, 2001, 2, 429-437.
103. Zhong, W., Wang, H., Herndier, B., Ganem, D. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc. Natl. Acad Sci. USA, 1996, 93, 6641-6646.
104. Scala, G., Quinto, I., Ruocco, M.R., Mallardo, M., Ambrosino, C., Squitieri, B., Tassone, P., Venuta, S. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1. J. Virol., 1993, 67, 2853-2861.
105. Mole, L., Ripich, S., Margolis, D., Holodniy, M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J. Infect Dis., 1997, 176, 766-770.
106. Pleskoff, O., Treboute, C., Brelot, A., Heveker, N., Seman, M., Alizon, M. Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. Science, 1997, 276, 1874-1878.
107. Varthakavi, V., Browning, P.J., Spearman, P. Human immunodeficiency virus replication in a primary effusion lymphoma cell line stimulates lytic-phase replication of Kaposi's sarcoma-associated herpesvirus. J. Virol., 1999, 73, 10329-10338.
108. Ploegh, H.L. Viral strategies of immune evasion. Science, 1998, 280, 248-253.
109. Brander, C., Suscovich, T., Lee, Y., Nguyen, P.T., O'Connor, P., Seebach, J., Jones, N.G., van Gorder, M., Walker, B.D., Scadden, D.T. Impaired CTL recognition of cells latently infected with Kaposi's sarcoma-associated herpes virus. J. Immunol., 2000, 165, 2077-2083.
110. Ishido, S., Wang, C., Lee, B.S., Cohen, G.B., Jung, J.U. Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J. Virol., 2000, 74, 5300-5309.
111. Ishido, S., Choi, J.K., Lee, B.S., Wang, C., DeMaria, M., Johnson, R.P., Cohen, G.B., Jung, J.U. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity, 2000, 13, 365-374.
112. Coscoy, L., Ganem, D. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc. Natl. Acad. Sci., USA, 2000, 97, 8051-8056.
113. Coscoy, L., Sanchez, D.J., Ganem, D. A novel class of herpesvirus-encoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition. J. Cell Biol., 2001, 155, 1265-1273.
114. Lee, B.S., Alvarez, X., Ishido, S., Lackner, A.A., Jung, J.U. Inhibition of intracellular transport of B cell antigen receptor complexes by Kaposi's sarcoma-associated herpesvirus K1. J. Exp. Med., 2000, 192, 11-21.
115. Hanahan, D., Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100, 57-70.
116. Lucas, K.G., Small, T.N., Heller, G., Dupont, B., O'Reilly, R.J. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood, 1996, 87, 2594-2603.
117. Tosato, G., Teruya-Feldstein, J., Setsuda, J., Pike, S.E., Jones, K.D., Jaffe, E.S. Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD. Springer Semin Immunopathol., 1998, 20, 405-423.
118. Setsuda, J., Teruya-Feldstein, J., Harris, N.L., Ferry, J.A., Sorbara, L., Gupta, G., Jaffe, E.S., Tosato, G. Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease. Am. J. Pathol., 1999, 155, 257-265.
119. Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., Komori, T., Kishimoto, S., Hirano, T., Kishimoto, T. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood, 1989, 74, 1360-1367.
120. Beck, J.T., Hsu, S.M., Wijdenes, J., Bataille, R., Klein, B., Vesole, D., Hayden, K., Jagannath, S., Barlogie, B. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N. Engl. J. Med., 1994, 330, 602-605.
121. Gherardi, R.K., Belec, L., Fromont, G., Divine, M., Malapert, D., Gaulard, P., Degos, J.D. Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome. Blood, 1994, 83, 2587-2593.
122. Nishimoto, N., Sasai, M., Shima, Y., Nakagawa, M., Matsumoto, T., Shirai, T., Kishimoto, T., Yoshizaki, K. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood, 2000, 95, 56-61.
123. Hirano, T., Ishihara, K., Hibi, M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene, 2000, 19, 2548-2556.
124. Fukada, T., Hibi, M., Yamanaka, Y., Takahashi-Tezuka, M., Fujitani, Y., Yamaguchi, T., Nakajima, K., Hirano, T. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity, 1996, 5, 449-460.
125. Leonard, W.J., O'Shea, J.J. Jaks and STATs: biological implications. Annu. Rev. Immunol., 1998, 16, 293-322.
126. Benjamin, D., Knobloch, T.J., Dayton, M.A. Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and-Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood, 1992, 80, 1289-1298.
127. Jones, D., Ballestas, M.E., Kaye, K.M., Gulizia, J.M., Winters, G.L., Fletcher, J., Scadden, D.T., Aster, J.C. Primary-effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient. N. Engl. J. Med., 1998, 339, 444-449.
128. Aoki, Y., Feldman, G.M., Tosato, G. Inhibition of STAT3 signaling induces apoptosis and decreases Survivin expression in primary effusion lymphoma. Blood, 2003, in press.
129. Bromberg, J.F., Wrzeszczynska, M.H., Devgan, G., Zhao, Y., Pestell, R.G., Albanese, C., Darnell, J.E., Jr. Stat3 as an oncogene. Cell, 1999, 98, 295-303.
130. Nielsen, M., Kaltoft, K., Nordahl, M., Ropke, C., Geisler, C., Mustelin, T., Dobson, P., Svejgaard, A., Odum, N. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc. Natl. Acad. Sci. USA, 1997, 94, 6764-6769.
131. Catlett-Falcone, R., Landowski, T.H., Oshiro, M.M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J.L., Nunez, G., Dalton, W.S., Jove, R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 1999, 10, 105-115.
132. Zhang, Y., Turkson, J., Carter-Su, C., Smithgall, T., Levitzki, A., Kraker, A., Krolewski, J.J., Medveczky, P., Jove, R. Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J. Biol. Chem., 2000, 275, 24935-24944.
133. Epling-Burnette, P.K., Liu, J.H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.M., Yang-Yen, H.F., Karras, J., Jove, R., Loughran, T.P., Jr. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest., 2001, 107, 351-362.
134. Alas, S., Bonavida, B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down- regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res., 2001, 61, 5137-5144.
135. Jones, K.D., Aoki, Y., Chang, Y., Moore, P.S., Yarchoan, R., Tosato, G. Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood, 1999, 94, 2871-2879.
136. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1995, 1, 27-31.
137. Carmeliet, P., Jain, R.K. Angiogenesis in cancer and other diseases. Nature, 2000, 407, 249-257.
138. Tosato, G., Sgadari, C., Taga, K., Jones, K.D., Pike, S.E., Rosenberg, A., Sechler, J.M., Magrath, I.T., Love, L.A., Bhatia, K. Regression of experimental Burkitt's lymphoma induced by Epstein-Barr virus-immortalized human B cells. Blood, 1994, 83, 776-784.
139. Angiolillo, A.L., Sgadari, C., Taub, D.D., Liao, F., Farber, J.M., Maheshwari, S., Kleinman, H.K., Reaman, G.H., Tosato, G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med., 1995, 182, 155-162.
140. Sgadari, C., Angiolillo, A.L., Cherney, B.W., Pike, S.E., Farber, J.M., Koniaris, L.G., Vanguri, P., Burd, P.R., Sheikh, N., Gupta, G., Teruya-Feldstein, J., Tosato, G. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc. Natl. Acad. Sci. USA, 1996, 93, 13791-13796.
141. Pike, S.E., Yao, L., Jones, K.D., Cherney, B., Appella, E., Sakaguchi, K., Nakhasi, H., Teruya-Feldstein, J., Wirth, P., Gupta, G., Tosato, G. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J. Exp. Med., 1998, 188, 2349-2356.
142. Yao, L., Sgadari, C., Furuke, K., Bloom, E.T., Teruya-Feldstein, J., Tosato, G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood, 1999, 93, 1612-1621.
143. Pike, S.E., Yao, L., Setsuda, J., Jones, K.D., Cherney, B., Appella, E., Sakaguchi, K., Nakhasi, H., Atreya, C.D., Teruya-Feldstein, J., Wirth, P., Gupta, G., Tosato, G. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood, 1999, 94, 2461-2468.
144. Yao, L., Pike, S.E., Setsuda, J., Parekh, J., Gupta, G., Raffeld, M., Jaffe, E.S., Tosato, G. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood, 2000, 96, 1900-1905.
145. Sgadari, C., Farber, J.M., Angiolillo, A.L., Liao, F., Teruya-Feldstein, J., Burd, P.R., Yao, L., Gupta, G., Kanegane, C., Tosato, G. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood, 1997, 89, 2635-2643.
146. Tulpule, A., Scadden, D.T., Espina, B.M., Cabriales, S., Howard, W., Shea, K., Gill, P.S. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J. Clin. Oncol., 2000, 18, 716-723.
147. Bertolini, F., Mancuso, P., Gobbi, A., Pruneri, G. The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp. Hematol., 2000, 28, 993-1000.
148. Aoki, Y., Tosato, G. Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomas. Leuk Lymphoma, 2001, 41, 229-237.
149. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J., Barlogie, B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med., 1999, 341, 1565-1571.
150. Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., Badros, A., Zangari, M., Anaissie, E., Epstein, J., Shaughnessy, J., Ayers, D., Spoon, D., Tricot, G. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood, 2001, 98, 492-494.
151. Ferrara, N. Vascular endothelial growth factor: molecular and biological aspects. Curr. Top Microbiol. Immunol., 1999, 237, 1-30.
152. Shibuya, M. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv. Cancer Res., 1995, 67, 281-316.
153. Murohara, T., Horowitz, J.R., Silver, M., Tsurumi, Y., Chen, D., Sullivan, A., Isner, J.M. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation, 1998, 97, 99-107.
154. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., Risau, W., Nagy, A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature, 1996, 380, 435-439.
155. Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K.S., Powell-Braxton, L., Hillan, K.J., Moore, M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature, 1996, 380, 439-442.
156. Dvorak, H.F., Nagy, J.A., Feng, D., Brown, L.F., Dvorak, A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top Microbiol. Immunol., 1999, 237, 97-132.
157. Ferrara, N., Winer, J., Burton, T., Rowland, A., Siegel, M., Phillips, H.S., Terrell, T., Keller, G.A., Levinson, A.D. Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. J. Clin. Invest., 1993, 91, 160-170.
158. Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S., Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 1983, 219, 983-985.
159. Luo, J.C., Yamaguchi, S., Shinkai, A., Shitara, K., Shibuya, M. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res., 1998, 58, 2652-2660.
160. Zebrowski, B.K., Liu, W., Ramirez, K., Akagi, Y., Mills, G.B., Ellis, L.M. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann. Surg. Oncol., 1999, 6, 373-378.
161. Aoki, Y., Tosato, G., Nambu, Y., Iwamoto, A., Yarchoan, R. Detection of vascular endothelial growth factor in AIDS-related primary effusion lymphomas. Blood, 2000, 95, 1109-1110.
162. Aoki, Y., Tosato, G. Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas. Blood, 1999, 94, 4247-4254.
163. Said, W., Chien, K., Takeuchi, S., Tasaka, T., Asou, H., Cho, S.K., de Vos, S., Cesarman, E., Knowles, D.M., Koeffler, H.P. Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells. Blood, 1996, 87, 4937-4943.
164. Foss, H.D., Araujo, I., Demel, G., Klotzbach, H., Hummel, M., Stein, H. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J. Pathol., 1997, 183, 44-50.
165. Nishi, J., Arimura, K., Utsunomiya, A., Yonezawa, S., Kawakami, K., Maeno, N., Ijichi, O., Ikarimoto, N., Nakata, M., Kitajima, I., Fukushige, T., Takamatsu, H., Miyata, K., Maruyama, I. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease. Br. J. Haematol., 1999, 104, 482-485.
166. Watanabe, O., Arimura, K., Kitajima, I., Osame, M., Maruyama, I. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet, 1996, 347, 702.
167. Stine, J.T., Wood, C., Hill, M., Epp, A., Raport, C.J., Schweickart, V.L., Endo, Y., Sasaki, T., Simmons, G., Boshoff, C., Clapham, P., Chang, Y., Moore, P., Gray, P.W., Chantry, D. KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood, 2000, 95, 1151-1157.
168. Albini, A., Benelli, R., Presta, M., Rusnati, M., Ziche, M., Rubartelli, A., Paglialunga, G., Bussolino, F., Noonan, D. HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene, 1996, 12, 289-297.
169. Chirivi, R.G., Taraboletti, G., Bani, M.R., Barra, L., Piccinini, G., Giacca, M., Bussolino, F., Giavazzi, R. Human immunodeficiency virus-1 (HIV-1)-Tat protein promotes migration of acquired immunodeficiency syndrome-related lymphoma cells and enhances their adhesion to endothelial cells. Blood, 1999, 94, 1747-1754.
170. Albini, A., Soldi, R., Giunciuglio, D., Giraudo, E., Benelli, R., Primo, L., Noonan, D., Salio, M., Camussi, G., Rockl, W., Bussolino, F. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk- 1/KDR receptor on vascular endothelial cells. Nat. Med., 1996, 2, 1371-1375.
171. Ensoli, B., Barillari, G., Salahuddin, S.Z., Gallo, R.C., Wong-Staal, F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature, 1990, 345, 84-86.
172. Vogel, J., Hinrichs, S.H., Reynolds, R.K., Luciw, P.A., Jay, G. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature, 1988, 335, 606-611.
173. Ascoli, V., Lo-Coco, F. Body cavity lymphoma. Curr. Opin. Pulm. Med, 2002, 8, 317-322.
174. Cattelan, A., Calabro, M., Gasperini, P., Aversa, S., Zanchetta, M., Meneghetti, F., De Rossi, A.A., Chieco-Bianchi, L. Acquired immunodeficiency syndrome-related kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J. Natl. Cancer Inst. Monogr., 2001, 28, 44-49.
175. Masood, R., Zhang, Y., Bond, M.W., Scadded, D.T., Moudgil, T., Law, R.E., Kaplan, M.H., Jung, B., Espina, B.M., Lunardi-Iskandar, Y., levine, A., Jill, P.S. Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood, 1995, 85, 3423-3430.
176. Richard, S., Croisille, L., Yvart, J., Casadeval, N., Eschwege, P., Aghakhani, N., David, P., Gaudric, A., Scigalla, P., Hermine, O. Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy. Blood, 2002, 99, 3851-3853.
177. Harrington, W., Jr., Sieczkowski, L., Sosa, C., Chan-a-Sue, S., Cai, J.P., Cabral, L., Wood, C. Activation of HHV-8 by HIV-1 tat. Lancet, 1997, 349, 774-775.
178. Schulz, T.F. Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). J. Gen. Virol., 1998, 79, 1573-1591.